Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Second Affiliated Hospital of Zhejiang University

ClinicalTrials.gov lists Second Affiliated Hospital of Zhejiang University as lead sponsor of 1,132 trials. It has 720 active development programs and 218 approved assets.

CN Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

200 0 2000 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 167 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 200 in 2026 and about 190 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (100 to 500), forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 2 trials are registered to start in 2027 or later.

This page covers Second Affiliated Hospital of Zhejiang University: 1,132 lead-sponsored trials and 1 legal-entity registration.

Get the Second Affiliated Hospital of Zhejiang University report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (518)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Stroke 67
Colorectal Neoplasms 56
Breast Neoplasms 38
Ischemic Stroke 33
Lung Neoplasms 31

Trials by start year as sponsor or collaborator (22)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 167
2025 181
2024 152
2023 130
2022 116
2021 139
2020 142
2019 76
2018 67
2017 45

Prediction, not a registry value: median of 36 months from start to primary completion across 209 trials still running at the 2026-10-09 snapshot; registered median of 15 months across 216 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (720)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Auricular point stimulation plus dexamethasone Nausea Phase 3 6
OXALIPLATIN Colorectal Neoplasms Phase 3 4
"Capecitabine" Colorectal Neoplasms Phase 3 4
Standard pharmacologic antiemetic regimen Nausea Phase 3 3
Standard Medical Treatment Stroke Phase 3 2

Approved assets (218)

Shown in this order: max phase first.

Approved assets
Drug Trials
CARBOPLATIN 6
TRASTUZUMAB 6
(CP-6890,550) Tofacitinib 5
PERTUZUMAB 5
Esketamine 4

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
63% hit target (n=98) 44% on time (n=101)

Journals published in (506)

Shown in this order: most published in first.

Journals published in
Journal Publications
The New England journal of medicine 46
Lancet (London, England) 24
Circulation 21
Journal of the American College of Cardiology 19
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 18

Organization relationships (120)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
West China Hospital Co sponsors trial with 18
The First Affiliated Hospital with Nanjing Medical University Co sponsors trial with 11
Affiliated Hospital of Jiaxing University Co sponsors trial with 10
The Central Hospital of Lishui City Co sponsors trial with 7
Shanghai Zhongshan Hospital Co sponsors trial with 7

Latest dated events (1,313)

Shown in this order: newest first.

Latest dated events
Date Event Source
2027-10-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2027-06-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-12-31 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-12-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-12-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (1,606)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ABCC1 Trial sponsor Named in trial inclusion criteria
ACVRL1 Trial sponsor Named in trial inclusion criteria
AGA Trial sponsor Named in trial inclusion criteria
AGA Trial sponsor Named in trial inclusion criteria
ALB Trial collaborator Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.